AlphaRx appoints clinical and regulatory expert to chair scientific advisory board

Markham, ON – May 11, 2004 – AlphaRx says it has appointed Dr Guy Ely to chair its scientific advisory board. Dr Guy Ely, a clinical and regulatory expert with significant experience in developing new drugs, will advise the company in Indaflex clinical program development. Dr Ely currently serves as vice president, clinical and medical affairs of Biomira where he is responsible for global clinical development and medical affairs.

Prior to his current position with Biomira, Dr Ely served as the vice president, clinical and medical affairs for Lorus Therapeutics where he directed the global clinical development of anti-cancer drugs. In addition, Dr Ely served as associate medical director of SmithKline Beecham. He was responsible for all clinical research and development activities, including the execution of close to 50 international clinical trials. He also served as manager, clinical research and medical advisor at Ciba-Geigy Canada, where he was responsible for the Phase I-IV clinical program of Voltaren 75 SR, a non steroidal anti-inflammatory drug (NSAID). The clinical data from this program were used in other countries to support approval of this product.

The scientific advisory board will be instrumental in implementing AlphaRx’s goal of advancing its lead pharmaceutical product into clinical phases.